NO BLEeding excess with antiplatelet treatment with thromboserin during coronary artery bypass grafting (CABG)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN59071456

Enrollment

120

Registered

2010-07-30

Start date

2009-01-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Cardiovascular

Interventions

Placebo or thromboserin 10 mg stat followed by 5 mg bd. Total duration of 12 months. Please note, this trial never started as the objectives were no longer viable.

Eligibility

Inclusion criteria

Inclusion criteria: The original protocol, which received ethical and MHRA approval states. All patients requiring cardiac surgery.

Exclusion criteria

Exclusion criteria: The original protocol, which received ethical and MHRA approval states. Patients with bradycardia or bradyarrhythmia, unless drug induced and the drug stopped (e.g. ß- adrenoreceptor antagonists). Patients treated with serotonin re-uptake inhibitors.

Design outcomes

Primary

Measure	Time frame
Platelet aggregate and thrombus growth	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026